Eloxx Pharmaceuticals: appoints Geno Germano and updates EXPRESS trial

What happened The filing says on Oct 19, 2026 the board increased the size of the board from 5 to 6 directors and appointed Geno J. Germano to fill the newly created vacancy. The filing says Mr. Germano will serve for a term expiring at the company’s annual meeting of stockholders to be held in 2027 and until his successor is duly elected and qualified or until his earlier death, disqualification, resignation or removal, and that the board determined he is “independent” under Nasdaq listing standards, the company’s policies, and SEC rules. The filing says on Oct 20, 2026 the company provided a corporate update reporting the appointment of T.R. Srinivas, M.D. as senior vice president and chief medical officer and the finalized design of EXPRESS, its global Phase 2 trial of exaluren in nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD).

Key details

• Board change: increased from 5 to 6 on Oct 19, 2026; Mr. Germano’s term expires at the 2027 annual meeting.
• Director compensation and arrangements: Mr. Germano entered into the company’s standard indemnity agreement (form filed as Exhibit 10.17 on the company’s Form 10-K filed Mar 17, 2026).
• Equity award: option to purchase 13,587 shares of common stock at an exercise price of $12.50 per share; vests in 24 substantially equal monthly installments, fully vested on the last day of the month of the second anniversary, subject to continued service.
• Mr. Germano background: 35-year industry experience; most recently president and CEO of Elucida Oncology, Inc. from Aug 2018 to Jun 2024; prior roles include president of Intrexon Corporation (Jun 2016 to Mar 2017) and group president of Pfizer’s global innovative pharma business (2014 to Feb 2016); various public and private board memberships listed in the filing.
• EXPRESS trial design and timing: designed to enroll approximately 60 adults with PKD1 or PKD2 nonsense mutations, randomized 1:1 to receive exaluren or placebo for 52 weeks; primary endpoint is the annualized rate of change in height-adjusted total kidney volume; first patient dosing expected in Q3 2027; topline data expected in H1 2029. Exaluren has received orphan drug designations for ADPKD in the United States and in Europe.

Why it may matter The filing reports Item 5.02 (departure of directors or certain officers; election of directors) and Item 8.01 (other events). Item 5.02 covers the board increase, the appointment of a director, his independence determination, indemnity agreement, and director equity award. Item 8.01 covers the appointment of a chief medical officer and the finalized design and timing for the EXPRESS Phase 2 trial of exaluren. A filing does not show why the insider traded or why the company acted.